Expressão diferencial dos transcritos do gene anexina A2 e do receptor do fator de crescimento semelhante à insulina no Câncer de Mama

Abstract

Considering that malignant neoplasms arise from the deregulation of cell signaling pathways, mechanisms related to Annexin A2 (ANXA2) have been described associated to mammary tumorigenesis. This protein is involved in the control of transduction pathways, such as PI3KAkT-mTOR, which can also be activated by the Insulin 1-like Growth Factor Receptor (IGFR1). Our study aimed to quantify the ANXA2 and IGFR1 transcripts by qPCR in Breast cell lines and to correlate them to Annexin A1 (ANXA1) mRNA levels, known more expressed in Breast Cancer Triple-negative (TNBC), a more aggressive subtype of the disease. The mammary cell lines MCF10A (non-tumorigenic), MCF7 (luminal A phenotype) and MDA-MB231 (triplenegative basal phenotype) were used. The comparative Ct method was previously validated and the data normalized with the reference gene Beta-2-microglobulin (B2M). The ANXA2 gene was significantly more expressed in MDA-MB231 cells compared to the other strains (P <0.01). IGFR1 transcripts were significantly more expressed in MCF7 (P <0.01) cells. The ANXA1 transcriptional expression profile was similar to ANXA2, and a positive correlation was observed between both (R = 0.99, P <0.01). No correlations were identified with IGFR1 transcripts. Our results suggest the Annexins presently studied as important markers for TNBC. Considering IGFR1, it has been shown to be overexpressed in the luminal BC, suggesting its possible use as an additional therapeutic target in this subtype. However, additional studies at the protein level are needed to better elucidate the synergism and function of these proteins in BC, especially in TNBC.